ACADIA Pharmaceuticals (NASDAQ:ACAD) is scheduled to release its earnings data after the market closes on Monday, February 26th. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.58) per share for the quarter.
Shares of ACADIA Pharmaceuticals (ACAD) opened at $30.92 on Monday. The company has a market capitalization of $3,840.00, a P/E ratio of -12.57 and a beta of 3.48. ACADIA Pharmaceuticals has a twelve month low of $25.06 and a twelve month high of $41.20.
In related news, EVP Glenn Baity sold 36,558 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $32.39, for a total value of $1,184,113.62. Following the sale, the executive vice president now owns 83,734 shares in the company, valued at approximately $2,712,144.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Laura Brege sold 25,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $30.06, for a total value of $751,500.00. Following the completion of the sale, the director now owns 15,000 shares in the company, valued at approximately $450,900. The disclosure for this sale can be found here. In the last 90 days, insiders sold 135,879 shares of company stock worth $4,175,649. 22.25% of the stock is owned by company insiders.
Several research firms have recently commented on ACAD. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, November 8th. BidaskClub raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. ValuEngine downgraded ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, Cowen reissued a “buy” rating and issued a $46.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. ACADIA Pharmaceuticals presently has an average rating of “Buy” and an average price target of $48.86.
WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/acadia-pharmaceuticals-acad-scheduled-to-post-earnings-on-monday.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.